US20080108838A1 - Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation - Google Patents
Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation Download PDFInfo
- Publication number
- US20080108838A1 US20080108838A1 US11/954,348 US95434807A US2008108838A1 US 20080108838 A1 US20080108838 A1 US 20080108838A1 US 95434807 A US95434807 A US 95434807A US 2008108838 A1 US2008108838 A1 US 2008108838A1
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- chem
- preparation
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 229930013356 epothilone Natural products 0.000 title claims abstract description 18
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title description 5
- YVXHZKKCZYLQOP-UHFFFAOYSA-N hept-1-yne Chemical class CCCCCC#C YVXHZKKCZYLQOP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 150000003883 epothilone derivatives Chemical class 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 19
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 239000000543 intermediate Substances 0.000 abstract description 7
- -1 heterocyclic radical Chemical class 0.000 description 16
- 0 *[C@@]12CCC[C@H](C)C(O)[C@@H]([3H])C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](C)CC1O2 Chemical compound *[C@@]12CCC[C@H](C)C(O)[C@@H]([3H])C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](C)CC1O2 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WIFAOWOUWDHNQT-ZETCQYMHSA-N C#CC[C@H](C)COC Chemical compound C#CC[C@H](C)COC WIFAOWOUWDHNQT-ZETCQYMHSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- YWWMSWJPIFAMQB-HIFPTAJRSA-N (6s)-6-methyl-7-(oxan-2-yloxy)hept-3-yn-2-ol Chemical compound CC(O)C#CC[C@H](C)COC1CCCCO1 YWWMSWJPIFAMQB-HIFPTAJRSA-N 0.000 description 2
- WVBGACDXLHXMGE-AMGKYWFPSA-N (6s)-6-methyl-7-(oxan-2-yloxy)hept-3-yn-2-one Chemical compound CC(=O)C#CC[C@H](C)COC1CCCCO1 WVBGACDXLHXMGE-AMGKYWFPSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QATYWYWXGPNTNI-AMGKYWFPSA-N (6s)-6-methyl-7-(oxan-2-yloxy)heptan-2-one Chemical compound CC(=O)CCC[C@H](C)COC1CCCCO1 QATYWYWXGPNTNI-AMGKYWFPSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004338 2,2,3-trimethylbutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- MDKSRUSRIYHCAX-VUWPPUDQSA-N 2-[(2s)-2-methylpent-4-ynoxy]oxane Chemical compound C#CC[C@H](C)COC1CCCCO1 MDKSRUSRIYHCAX-VUWPPUDQSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- XPSHHPUSHXWALI-QMMMGPOBSA-N COC[C@@H](C)CCCC(C)=O Chemical compound COC[C@@H](C)CCCC(C)=O XPSHHPUSHXWALI-QMMMGPOBSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001532577 Sorangium Species 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- GRHZLQBPAJAHDM-SPRQWYLLSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound CC1=CC=CC(C)=C1OCC(=O)N[C@H]([C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 GRHZLQBPAJAHDM-SPRQWYLLSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the goal of the present invention is to provide a novel synthetic process for the production of intermediates used in the synthesis of epothilones and epothilone derivatives.
- the new route starts from economical starting materials, yields intermediate products in high enantiomeric purity, in high chemical purity, in good yields and allows an industrial-scale production.
- the prior art has the disadvantage of requiring either the use of expensive chiral auxiliary agents (in some cases at a temperature of ⁇ 100° C.), expensive starting materials, or expensive purification process. Therefore, the new synthesis offers many important advantages.
- the present invention relates to a synthetic route for the production of compounds of general formula IA, a key structural unit used in total epothilone or epothilone derivatives syntheses: wherein
- the invention especially relates to the synthesis of the compounds of formula IA (see reaction sequence) starting from compounds of general formula IV, a synthesis which is largely unrelated to any synthesis found in the literature related to epothilone syntheses and which has many important advantages: wherein X 1 has the same meaning as hereinbefore given under formula IA.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivatives, to certain compounds used to produce these key intermediates and to a process to produce said compounds.
Description
- The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivatives, to certain compounds used to produce these key intermediates and to a process to produce said compounds. The process for the production of the key intermediates starts from readily available and cheap starting materials, yields products in high enantiomeric purity, in high chemical purity, in good yields and allows an industrial-scale production.
- The invention is used in the synthesis of structural unit B of natural and synthetically-modified epothilones or derivatives. Epothilones are 16-membered macrolide compounds that find utility in the pharmaceutical field. Epothilones have been isolated from cultures of Myxobacterium Sorangium Cellosum and are representatives of a class of promising anti-tumor agents that were tested and found to be effective against a number of cancer lines. A survey of the syntheses for these compounds has been described by J. Mulzer et al., in Monatsh. Chem. 2000, 131, 205-238. These agents have the same biological mode of action as paclitaxel and other taxanes (see for paclitaxel, D. G. I. Kingston, Chem. Commun. 2001, 867-880), however, epothilones have also been shown to be active against a number of resistant cell lines (see S. J. Stachel et al., Curr. Pharmaceut. Design 2001, 7, 1277-1290; K.-H. Altmann, Curr. Opin. Chem. Biol. 2001, 5, 424-431).
In addition to natural epothilones, the literature describes a number of synthetic epothilone derivatives that vary for the most part in radicals M, T and R. In most cases, M stands for a heterocyclic radical. For natural epothilone A, R stands for hydrogen, whereas for epothilone B, R stands for methyl. - Most syntheses of the natural epothilones and the synthetic epothilone derivatives involve the joining of several structural units. Structural unit B, which represents the C11-C16 fragment, proved to be one of the strategically important structural units. It was, therefore, of great importance to develop an economical process for the production of structural unit B of epothilone syntheses.
- In most cases, the epothilone is synthesized by inserting structural unit B as a protected hydroxy ketone (formula I, X1=protecting group). The C1-C16 linkage is carried-out by means of a Wittig reaction, while the C10-C11 linkage is carried-out by means of an aldol reaction. Both reactions have already been described in the literature (see K. C. Nicolaou et al., Tetrahedron 1998, 54, 7127-7166; Angew. Chem. 1998, 110, 85-89; Chem. Eur. J. 1997, 3, 1971-1986; J. Am. Chem. Soc. 1997, 119, 7974-7991).
- A possible preparation of structural unit B is described in, for example, WO 99/07692 and WO 00/47584. However, the syntheses presented there are expensive and based on the introduction of chirality using an expensive chiral auxiliary agent and thus not usable or feasible for an industrial-scale production of epothilone or epothilone derivatives.
- WO 98/25929 and K. C. Nicolaou et al., J. Am. Chem. Soc. 1997, 119, 7974-7991 also describe tedious preparations of structural unit B by means of a chiral auxiliary agent. These preparations have additionally the technical disadvantage of introducing chirality at a reaction temperature of −100° C.
- A further synthesis is described in Helv. Chim. Acta 1990, 73, 733-738, whereby a compound of formula I (X1═H) is also used. This compound, however, is obtained from a costly synthesis involving diterpenes as starting materials (see also Chimia 1973, 27, 97-99) and results in an enantiomeric purity of only approx. 80 to 85%.
- Moreover, it can be said that the processes described in the literature require a purification process involving several chromatographic steps, which is rather disadvantageous from a production stand point because this results in many general technical problems such as reconditioning of solvents, avoiding contamination of the environment, high cost, etc.
- Due to low total yields, low space-time yields and high excesses of reagents, it has not been possible with any of the processes available to a person skilled in the art to economically prepare structural unit B on an industrial-scale. There was therefore a need for such an industrial-scale process and capable of being implemented on an operational scale, that allows for a universally usable intermediate compound for the production of structural unit B in the total synthesis of epothilones and epothilone derivatives.
- The goal of the present invention is to provide a novel synthetic process for the production of intermediates used in the synthesis of epothilones and epothilone derivatives. In contrast to other published syntheses, the new route starts from economical starting materials, yields intermediate products in high enantiomeric purity, in high chemical purity, in good yields and allows an industrial-scale production. The prior art has the disadvantage of requiring either the use of expensive chiral auxiliary agents (in some cases at a temperature of −100° C.), expensive starting materials, or expensive purification process. Therefore, the new synthesis offers many important advantages.
-
- R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl, alkyl being preferred; and
- X1 is an oxygen protecting group.
- The compounds of formula IA can then be used for the synthesis of epothilones and epothilone derivatives via various steps known in the art.
-
- The invention especially relates to the synthesis of the compounds of formula IA (see reaction sequence) starting from compounds of general formula IV, a synthesis which is largely unrelated to any synthesis found in the literature related to epothilone syntheses and which has many important advantages:
wherein X1 has the same meaning as hereinbefore given under formula IA. - Within the present description, the general definitions used hereinbefore and hereinafter preferably have the following meaning:
- Alkyl can be a linear or branched alkyl, preferably having up to and including 12 carbon atoms. Examples of alkyl groups are linear alkyls such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl or n-dodecyl group or branched alkyl groups such as the iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, neo-pentyl, 2-pethylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2-methylhexyl, 2,2-dimethylpentyl, 2,2,3-trimethylbutyl or 2,3,3-trimethylbutyl group. Especially preferred are methyl and ethyl.
- Examples of a substituted alkyl include —CH2-Halogen or —C(Halogen)3, especially preferred are —CH2F and CF3.
- A protecting group can be selected from the group comprising a silyl protecting group such as trimethylsilyl, tert-butyldimethylsilyl, triethylsilyl, tri(iso-propyl)silyl, dimethylphenylsilyl; lower alkanoyl, such as acetyl; benzoyl; tetrahydropyranyl; Mom protecting group, Mem protecting group; benzyl or substituted benzyl radicals such as 4-methoxybenzyl; or any other protecting group known from the literature (see for example T. W. Green, Protective Groups in Organic Synthesis, John Wiley & Sons N.Y., 1981; P. J. Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, 1994). Preferred are tetrahydropyranyl (THP) and tert-butyldimethylsilyl (TBDMS), with THP being especially preferred.
- The process steps making up the process of the invention and the preferred aspects thereof can be described preferably as follows:
- The reaction sequence starts with a compound of general formula IV as hereinbefore described which is reacted with an aldehyde of general formula V:
RCHO V
wherein R is as hereinbefore described, under reaction conditions known to a person skilled in the art for such acetylene additions to aldehydes (see Shun, Annabelle L. K. Shi et al., J. Org. Chem., 2003, 68, 4, 1339-1347; Mukai, Chisato et al., J. Org. Chem., 2003, 68, 4, 1376-1385; Clark, J. Stephen et al., Org. Lett., 2003, 5, 1, 89-92; Chun, Jiong et al., J. Org. Chem., 2003, 68, 2, 348-354; Nomura, Izumi et al., Org.Lett., 2002, 4, 24, 4301-4304; Nielsen, Thomas E. et al., J. Org. Chem., 2002, 67, 18, 6366-6371; Kiyota, Hiromasa et al., Syn.Lett., 2003, 2, 219-220; Bailey et al., J. Chem. Soc., 1957, 3027, 3031; Nayler et al., J. Chem. Soc., 1955, 3037, 3045; Moureu, Bull. Soc.Chim.Fr., 33, 155; Theus et al., Helv.Chim.Acta, 1955, 38, 239, 249; Gredy, C.R.Hebd.Seances Acad. Sci., 1934, 199, 153; Ann.Chim.(Paris), <11> 4, 1935, 5, 36); preferably the alkyne is deprotonated at a temperature between −78 to 0° C. in an aprotic solvent, such as methyl-tert-butyl ether, 2-methyl-THF, dioxane, toluene, or THF, with a strong base such as BuLi, LDA or Li, Na, K-HMDS, or Grignard solution, such as MeMgCl, MeMgBr or isopropyl-MgBr, and subsequently added to the aldehyde, yielding a compound of general formula III as hereinbefore described; compound of general formula III is then oxidized with an oxidizing agent known to a person skilled in the art (see for example Shun, Annabelle L. K. Shi et al., J. Org. Chem., 2003, 68, 4, 1339-1347; Clark, J. Stephen et al., Org.Lett., 2003, 5,1,89-92; Chun, Jiong et al., J. Org. Chem., 2003, 68, 2, 348-354; Quesnelle, Claude A. et al., Bioorg. Med. Chem. Lett., 2003, 13, 3, 519-524; Barriga, Susana et al., J. Org. Chem., 2002, 67, 18, 6439-6448; Suzuki, Keisuke et al., Org.Lett., 2002, 4, 16, 2739-2742; Claeys, Sandra et al., Eur. J. Org. Chem., 2002, 6, 1051-1062; Tanaka, Katsunao et al., Bioorg. Med. Chem. Lett., 2002, 12, 4, 623-628; Rodriguez, David et al., Tetrahedron Lett., 2002, 43, 15, 2717-2720; Tanaka, Koichi et al., J. Chem. Soc.Perkin Trans., 2002, 1, 6, 713-714; Hao, Junliang et al., Tetrahedron Lett., 2002, 43, 1, 1-2; Hiegel et al., Synthetic Commun., 1992, 22(11), 1589; De Mico et al., J. Org. Chem., 1997, 62, 6974), especially manganese dioxide in THF, TEMPO oxidation, trichloroisocyanuric acid or under Swern oxidation conditions, to yield a compound of general formula II as hereinbefore described; the triple bond of compound of general formula II is then reduced using processes known to a person skilled in the art (see for example Crombie et al., J. Chem. Soc., 1958, 4435, 4443; Braude et al., J. Chem. Soc., 1949, 607, 613; Taber, Douglass F. et al., J. Org. Chem., 2002, 67, 23, 8273-8275; Bowden et al., J. Chem. Soc., 1946, 52; Fazio, Fabio et al., Tetrahedron Lett., 2002, 43, 5, 811-814; Gonzalez, Isabel C. et al. J. Amer. Chem. Soc., 2000, 122, 38, 9099-9108; Brimble, Margaret A. et al. Aust.J. Chem., 2000, 53, 10, 845-852); preferably the reduction is done under catalytic hydrogenation conditions, using Pd on carbon in THF, as well as in the presence of acetic acid esters, lower alcohols such as methanol, ethanol, isopropanol, 2-methyl-THF, at a temperature between 0 to 50° C., under 5 to 10 bar of pressure, and for a period of 1 to 10 hours, to yield a compound of general formula IA. - Compounds of general formula IV are known in the literature and can be prepared according to methods known to a person skilled in the art such as:
- For X1=TBS: Ireland, Robert E. et al., Tetrahedron, 1997, 53, 39, 13221-13256; Bhatt, Ulhas et al., J. Org. Chem., 2001, 66, 5, 1885-1893; Yan, Jingbo et al., J. Org. Chem., 1999, 64, 4, 1291-1301.
- For X1=benzyl: Takle, Andrew et al., Tetrahedron, 1990, 46, 13/14, 4503-4516; Ireland, Robert E. et al., J. Org. Chem., 1992, 57, 19, 5071-5073.
- For X1=tert-butyldiphenylsilyl: Culshaw, David et al., Tetrahedron Lett., 1985, 26, 47, 5837-5840.
- For X1=MOM: Williams, David R. et al., J. Amer. Chem. Soc., 1989, 111, 5, 1923-1925.
- For X1=THP: Baker, Raymond et al., Tetrahedron Lett., 1986, 27, 28, 3311-3314; Ireland, Robert E. et al., Tetrahedron, 1997, 53, 39, 13221-13256.
- Alternatively, compounds of general formula II can be directly obtained by the reaction of a compound of general formula IV as hereinbefore described with an activated acid derivative of general formula VI,
wherein R is as hereinbefore described, and X is an appropriate leaving group, preferably halogen, —OCOR1, OR1, imidazole, 4-nitrophenol, Weinreb residue, or mixed anhydrides, wherein R1 is alkyl. Compounds of general formula II are then subsequently converted to compounds of general formula IA as hereinbefore described in the reaction sequence. The reaction of compounds such as IV and VI has, for example, been described in the following literature:
Naka, Tadaatsu et al., Tetrahedron Lett., 2003, 44, 3, 443-446;
Nielsen, Thomas E. et al., J. Org. Chem., 2002, 67, 21, 7309-7313;
Hakogi, Toshikazu et al., Bioorg. Med. Chem. Lett., 2003, 13, 4, 661-664;
Nielsen, Thomas E. et al., J. Org. Chem., 2002, 67, 21, 7309-7313; and
Knoelker, Hans-Joachim et al., Tetrahedron, 2002, 58, 44, 8937-8946. - It also proved to be advantageous in some cases to prepare compounds of general formula IA directly from compounds of general formula VII,
by oxidating compounds of general formula VII using methods for the oxidation of secondary alcohols known to a person skilled in the art (see literature cited above). - Compounds of general formula VII are obtained from compounds of general formula III by reduction of the triple bond according to the methods hereinbefore described.
- Another alternative, is the hydrogenation of compounds of general formula II to corresponding alkenes of general formula VIII,
followed by the oxidation of the corresponding alkenes, and their subsequent further hydrogenation to compounds of the general formula IA, or if the allyl alcohol VIII directly rearranges, compounds of general formula IA can be obtained as is described, for example in Paul, C.R.Hebd. Seances Acad.Sci., 1939, 208, 1320; Bull. Soc.Chim.Fr., 1941, <5>8, 509; and Cheeseman et al., J. Chem. Soc., 1949, 2034; Uma, Ramaling a et al., Eur.J. Org. Chem., 2001, 10, 3141-3146; Cherkaoui, Hassan et al., Tetrahedron, 2001, 57, 12, 2379-2384; Lee, Donghyun et al., Org.Lett., 2000, 2, 15, 2377-2380. - The reactions described above are preferably carried out under the conditions analogous to those given in the examples. The following examples are intended to illustrate the invention without being intended to restrict the scope of the invention:
- 2450 ml n-BuLi solution, 1.6 M, in hexane is added dropwise to a 650 g solution (3.566 mol) of (RS)-2-{[(S)-2-methylpent-4-in-1-yl]oxy}-3,4,5,6-tetrahydro-2H-pyrane (prepared in accordance with Ireland, Robert E. et al., Tetrahedron, 1997, 53, 39, 13221-13256.) in 325 ml of THF at −10° C. A solution of 310 g acetaldehyde in 1200 ml THF is then added dropwise. After 30 min., 3250 ml MTBE (methyl-tert.butylether) is added and 3250 ml 10% aq NH4Cl is added and further stirred for 10 min. The organic phase is washed twice with 1300 ml H2O each and concentrated in vacuo to dryness. 930 g of product is obtained. The obtained product is directly used in the subsequent step.
- Yield: approx. 100% (according to DC quantitatively)
- Elementary Analysis
Calc. C 68.99 H 9.80 Found C 68.75 H 10.03 - 1H-NMR (CD2Cl2), 400 MHz
- 1H (ppm)/number of H
- 1.00 (3H)
- 1.4 (3H)
- 1.50−1.83 (6H)
- 1.92 (1H)
- 2.15+2.33 (2H)
- 3.25+3.6 (2H)
- 3.45+3.85 (2H)
- 4.48 (1H)
- 4.56 (1H)
- A 300 g (1.3255 mol) solution of (2RS,6S)-6-methyl-7-[(RS)-(3,4,5,6-tetrahydro-2H-pyran-2-yl)oxy]hept-3-in-2-ol, dissolved in 600 ml of THF, is added by stirring to a suspension of 1500 g manganese dioxide in 2250 ml of THF, and stirring is continued at room temperature for 48 hours. The suspension is then filtered over silica gel and the solvent is removed in vacuo. 280 g of the product is obtained.
- Yield: 94.1% of the theory
- Elementary analysis:
Calc. C 69.61 H 8.99 Found C 69.42 H 9.16 - 1H-NMR (CD2Cl2), 400 MHz
- 1H (ppm)/number of H
- 1.03 (3H)
- 1.5-1.85 (6H)
- 2.04 (1H)
- 2.3 (3H)
- 2.35+2.53 (2H)
- 3.2-3.3+3.6-3.65 (2H)
- 3.5+3.8 (2H)
- 4.55 (1H)
- A 50 g solution (222.9 mmol) of (S)-6-methyl-7-[(RS)-(3,4,5,6-tetrahydro-2H-pyran-2-yl)oxy]hept-3-in-2-one and 5 g palladium on carbon (10% Pd/C) in 400 ml of THF is hydrogenated for one hour at 8 bar hydrogen at room temperature. The catalyst is then filtered off, rewashed with little solvent and the solvent is removed in vacuo. 50.9 g of product is obtained.
- Yield: approx. 100% of the theory. (According to DC quantitatively)
- Elementary analysis:
Calc. C 68.38 H 10.59 Found C 68.18 H 10.71 - 1H-NMR (CDCl3), 400 MHz
- 1H (ppm)/number of H
- 0.91/0.93 (3H)
- 1.0-1.9 (11H)
- 2.13 (3H)
- 2.42 (2H)
- 3.19 (1H)
- 3.4-3.6 (2H)
- 3.85 (1H)
- 4.55 (1H)
Claims (5)
1. A process for preparing an epothilone or an epothilone derivative comprising reacting a compound represented by formula IA,
wherein R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and X1 is an oxygen protecting group;
comprising reacting a compound of formula IV,
wherein X1 is as defined above, with an aldehyde of formula V,
RCHO V
wherein R is as defined above, in the presence of a suitable base to form a compound of formula III,
wherein R and X1 are as defined above, reacting compound of formula III with a suitable oxidizing agent to form a compound of formula II,
wherein R and X1 are as defined above, and subsequently reacting compound II with a suitable reducing agent to form said compound of formula IA.
2. A process for preparing a compound represented by formula IA,
wherein R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and X1 is an oxygen protecting group;
comprising reacting a compound of formula IV,
wherein X1 is as defined above, with an activated acid derivative of formula VI,
wherein R is as described above; and X is a Weinreb residue, in the presence of a suitable base to form a compound of formula II,
wherein R and X1 are as defined above, and subsequently reacting the compound of formula II with a suitable reducing agent to form said compound of formula IA.
3-13. (canceled)
15-26. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/954,348 US20080108838A1 (en) | 2004-04-22 | 2007-12-12 | Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090157.1 | 2004-04-22 | ||
EP04090157A EP1589011A1 (en) | 2004-04-22 | 2004-04-22 | Novel chiral heptyne derivates for the preparation of epothilones and processes for their preparation |
US11/110,959 US7326798B2 (en) | 2004-04-22 | 2005-04-21 | Chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
US11/954,348 US20080108838A1 (en) | 2004-04-22 | 2007-12-12 | Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,959 Continuation US7326798B2 (en) | 2004-04-22 | 2005-04-21 | Chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080108838A1 true US20080108838A1 (en) | 2008-05-08 |
Family
ID=34928801
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,959 Expired - Fee Related US7326798B2 (en) | 2004-04-22 | 2005-04-21 | Chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
US11/954,348 Abandoned US20080108838A1 (en) | 2004-04-22 | 2007-12-12 | Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,959 Expired - Fee Related US7326798B2 (en) | 2004-04-22 | 2005-04-21 | Chiral heptyne derivatives for the preparation of epothilones and processes for their preparation |
Country Status (18)
Country | Link |
---|---|
US (2) | US7326798B2 (en) |
EP (2) | EP1589011A1 (en) |
JP (1) | JP2007533700A (en) |
CN (1) | CN1942462B (en) |
AT (1) | ATE374758T1 (en) |
AU (1) | AU2005235376A1 (en) |
BR (1) | BRPI0510109A (en) |
CA (1) | CA2560455A1 (en) |
DE (1) | DE602005002750T2 (en) |
DK (1) | DK1758875T3 (en) |
ES (1) | ES2293574T3 (en) |
MX (1) | MXPA06012212A (en) |
PL (1) | PL1758875T3 (en) |
PT (1) | PT1758875E (en) |
RU (1) | RU2006140967A (en) |
SI (1) | SI1758875T1 (en) |
WO (1) | WO2005101950A1 (en) |
ZA (1) | ZA200609677B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114199A1 (en) | 2006-03-28 | 2007-10-11 | Sumitomo Chemical Company, Limited | Process for producing optically active (s)-7-hydroxy-6-methylheptane-2-one and precursor thereof |
JP6446271B2 (en) | 2014-01-08 | 2018-12-26 | クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc | Device for blocking perival leakage |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6320045B1 (en) * | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9810659D0 (en) | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
EE200100422A (en) * | 1999-02-11 | 2002-12-16 | Schering Aktiengesellschaft | Epothilone derivatives, process for their preparation and pharmaceutical use |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
-
2004
- 2004-04-22 EP EP04090157A patent/EP1589011A1/en not_active Withdrawn
-
2005
- 2005-04-21 CN CN2005800116115A patent/CN1942462B/en not_active Expired - Fee Related
- 2005-04-21 RU RU2006140967/04A patent/RU2006140967A/en not_active Application Discontinuation
- 2005-04-21 WO PCT/EP2005/004492 patent/WO2005101950A1/en active Application Filing
- 2005-04-21 PL PL05740374T patent/PL1758875T3/en unknown
- 2005-04-21 US US11/110,959 patent/US7326798B2/en not_active Expired - Fee Related
- 2005-04-21 AU AU2005235376A patent/AU2005235376A1/en not_active Abandoned
- 2005-04-21 DE DE602005002750T patent/DE602005002750T2/en active Active
- 2005-04-21 AT AT05740374T patent/ATE374758T1/en not_active IP Right Cessation
- 2005-04-21 CA CA002560455A patent/CA2560455A1/en not_active Abandoned
- 2005-04-21 EP EP05740374A patent/EP1758875B1/en active Active
- 2005-04-21 BR BRPI0510109-3A patent/BRPI0510109A/en not_active IP Right Cessation
- 2005-04-21 DK DK05740374T patent/DK1758875T3/en active
- 2005-04-21 JP JP2007508870A patent/JP2007533700A/en active Pending
- 2005-04-21 PT PT05740374T patent/PT1758875E/en unknown
- 2005-04-21 MX MXPA06012212A patent/MXPA06012212A/en not_active Application Discontinuation
- 2005-04-21 SI SI200530107T patent/SI1758875T1/en unknown
- 2005-04-21 ES ES05740374T patent/ES2293574T3/en active Active
-
2006
- 2006-11-21 ZA ZA200609677A patent/ZA200609677B/en unknown
-
2007
- 2007-12-12 US US11/954,348 patent/US20080108838A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6320045B1 (en) * | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
Also Published As
Publication number | Publication date |
---|---|
CN1942462A (en) | 2007-04-04 |
WO2005101950A1 (en) | 2005-11-03 |
PL1758875T3 (en) | 2008-02-29 |
CA2560455A1 (en) | 2005-11-03 |
US20060100442A1 (en) | 2006-05-11 |
ES2293574T3 (en) | 2008-03-16 |
SI1758875T1 (en) | 2008-02-29 |
MXPA06012212A (en) | 2007-04-17 |
EP1589011A1 (en) | 2005-10-26 |
JP2007533700A (en) | 2007-11-22 |
EP1758875A1 (en) | 2007-03-07 |
ATE374758T1 (en) | 2007-10-15 |
EP1758875B1 (en) | 2007-10-03 |
US7326798B2 (en) | 2008-02-05 |
DE602005002750D1 (en) | 2007-11-15 |
CN1942462B (en) | 2011-05-25 |
DE602005002750T2 (en) | 2008-07-17 |
DK1758875T3 (en) | 2008-01-21 |
PT1758875E (en) | 2007-12-14 |
BRPI0510109A (en) | 2007-10-30 |
RU2006140967A (en) | 2008-05-27 |
AU2005235376A1 (en) | 2005-11-03 |
ZA200609677B (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5334740A (en) | Cyclohexanetriol derivatives | |
EP0385733B1 (en) | Process for preparing optically active 6-t-butoxy-3,5-dihydroxyhexanoic esters | |
US8269001B2 (en) | Process for the synthesis of HMG-CoA reductase inhibitors | |
US10538539B2 (en) | Method for preparing 3-((2S, 5S)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl) propanol derivative, and intermediate therefor | |
US20080108838A1 (en) | Novel chiral heptyne derivatives for the preparation of epothilones and processes for their preparation | |
JP4301810B2 (en) | Process for producing intermediates for the production of discodelmoride and discodermolide analogues | |
US11046663B2 (en) | Entecavir intermediate, synthetic method thereof and synthetic method for entecavir | |
KR20070027536A (en) | Chiral heptin derivatives for the preparation of epothilones and methods for their preparation | |
US20100076199A1 (en) | Process for the preparation of substituted pyridone carboxylic acids | |
US8030503B2 (en) | Process for the preparation of epothilones | |
US8410305B2 (en) | Intermediates and methods for the preparation of epothilones | |
US6420612B1 (en) | Bicycloheptene derivatives and processes for the preparation of the same | |
US6495725B2 (en) | Process for the preparation of optically active enones and intermediates thereof | |
US20110301370A1 (en) | Method for preparing oreganic acid | |
US7084281B2 (en) | Synthesis of dihalohydrins and tri- and tetra-substituted olefins | |
US20070142675A1 (en) | Method for producing c1-c15 fragments of epothilones and the derivatives thereof | |
JPH10251183A (en) | Synthetic intermediate useful for synthesizing a-ring moiety of vitamin d derivative, its production and usage thereof | |
US20060030720A1 (en) | Method for synthesizing macrosphelides | |
JP2001240575A5 (en) | ||
EP2311841A1 (en) | Method for obtaining zaragozic acid and derivatives thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |